Skip to content

Physical Fitness, Cardiovascular and Brain Health

Physical Fitness, Cardiovascular and Brain Health

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01341145
Enrollment
41
Registered
2011-04-25
Start date
2011-03-01
Completion date
2014-04-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

hypertension, aerobic exercise, relaxation, functional magnetic resonance imaging (fMRI), magnetic resonance spectroscopy (MRS), brain health

Brief summary

The goal of this study is to determine if aerobic exercise or progressive muscle relaxation is associated with changes in cardiovascular health, brain function, and cognition.

Detailed description

Cognition is the most important determinant of health status, quality of life and functional ability in older age. Therefore, early interventions that preserve and enhance cognitive function are crucial for ensuring successful aging. The most common treatable risk factor for late-life cognitive impairment is midlife hypertension (HTN). One highly promising intervention strategy is aerobic exercise as it has been associated cognitive benefits in non-demented older adults. However, it is still unclear whether this benefit is due simply to prevention of other risk factors (e.g., reductions in blood pressure) or if exercise can reverse the negative effects of HTN on the brain. The goals of the current study are to employ sensitive measures of neuroimaging and cognition in order to 1).Compare cerebral health in endurance trained versus sedentary middle aged adults with normal or borderline to stage 1 hypertension, 2). measure the effects of exercise training in previously sedentary middle aged adults adults with normal or borderline to stage 1 hypertension, and 3). examine if exercise-related differences and changes in neural integrity and cognition are mediated by systemic vascular health.

Interventions

BEHAVIORALAerobic Exercise

12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine

BEHAVIORALRelaxation

12-week progressive muscle relaxation program (active control)

Sponsors

University of Texas at Austin
Lead SponsorOTHER
American Federation for Aging Research
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Sedentary adults Participants will be classified as sedentary if they have not engaged in regular physical exercise for at least one year prior to study enrollment. * Ages 45-65 * Normal blood pressure or Borderline or stage 1 hypertension Borderline hypertension will be defined as systolic blood pressure between 120-139 mmHg and/or diastolic blood pressure between 80-89 mmHg. Stage 1 hypertension will be defined as systolic blood pressure between 140-159 mmHg and/or diastolic blood pressure between 90-99 mmHg.

Exclusion criteria

* Signs or symptoms of chronic heart disease * Smoking (current or within the past 6 months) * Peripheral artery disease (ankle-brachial index\<0.9) * Diabetes (fasting blood glucose\>126 mg/L) * Orthopedic problems that would prohibit participants from participating in exercise. * Axis I psychiatric disorder * Magnetic resonance contraindications * Baseline Intellectual Quotient \< 70 * Below chance performance on the practice items of the cognitive tasks * Evidence of large vessel stroke on magnetic resonance imaging

Design outcomes

Primary

MeasureTime frameDescription
Percent signal change in Blood oxygen level-dependent (BOLD) response to a working memory taskchange from baseline in blood oxygen level-dependent (BOLD) response to WM task at 14 weeksBlood oxygen level-dependent (BOLD) functional magnetic resonance imaging (fMRI) during 2-Back working memory task
N-acetyl aspartate (NAA) concentrationchange from baseline in N-acetyl aspartate (NAA) concentration at 14 weeksMagnetic resonance spectroscopy (MRS) measurements of N-acetyl-aspartate (NAA)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAndreana Haley, PhD

University of Texas at Austin

PRINCIPAL_INVESTIGATORHirofumi Tanaka, Ph.D.

University of Texas at Austin

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026